MedTrace Logo

Seborrheic Dermatitis

Disease

Related News

Phase III Clascoterone Data Shows Sustained Hair Growth; Scalp SD Metabolomics Reveals Key Inflammatory Markers

Cosmo Pharmaceuticals reported positive 12-month Phase III data for Clascoterone 5% topical solution in male androgenetic alopecia, showing sustained hair growth and a safety profile comparable to vehicle. A separate metabolomics study characterized key inflammatory markers in scalp seborrheic dermatitis, identifying Malassezia fungi and specific free fatty acids as central drivers of the condition.

Arcutis draws focus to Zoryve data, FDA filings and Q4 expectations

Arcutis is in focus after new Phase 3 extension data for Zoryve cream 0.05% in young children with atopic dermatitis and ahead of its Feb. 25 Q4 results. Investors are also watching recent FDA actions and pipeline updates for additional pediatric and dermatology indications.

Related Clinical Trials

NCT ID Title Status Phase
NCT07734441

The Effectiveness of Itraconazole Pulse Therapy vs Topical 2% Ketoconazole in the Treatment of Moderate to Severe Seborrheic Dermatitis of Scalp.

 RECRUITING EARLY_PHASE1
NCT07683806

Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

 NOT_YET_RECRUITING PHASE3
NCT07641686

A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients

 RECRUITING NA
NCT07404033

ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis

 RECRUITING PHASE1
NCT07063615

Safety and Efficacy of a Topical Cream in Mild-to-Moderate Seborrheic Dermatitis

 COMPLETED NA
NCT06013371

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

 TERMINATED PHASE2
NCT05319444

Cleansing Device for the Treatment of Scalp and Hair Conditions

 TERMINATED NA